



If the following information is not complete, correct, or legible, the SA process can be delayed.
Please use one form per member.

MEMBER INFORMATION

Last name:

Grid for last name input

First name:

Grid for first name input

Medicaid ID number:

Grid for Medicaid ID number input

Date of birth:

Grid for date of birth input

Gender: Male Female

Weight in kilograms:

PRESCRIBER INFORMATION

Last name:

Grid for last name input

First name:

Grid for first name input

NPI number:

Grid for NPI number input

Phone number:

Grid for phone number input

Fax number:

Grid for fax number input

DRUG INFORMATION

This request is for: Short-acting opioid Long-acting opioid BOTH (check all that apply)

Service authorization is required for:

- 1. All long-acting opioids
2. Any short-acting opioid prescribed for more than 7 days or two 7-day supplies in a 60-day period.
3. Any cumulative opioid prescription exceeding 90 morphine milligram equivalents (MME) per day.

Long-acting opioids (LAOs): LAOs are indicated for members with chronic, moderate to severe pain who require daily, around-the-clock opioid treatment and require a service authorization (SA) form.

www.viriniamedicaidpharmacyservices.com/provider/external/medicaid/vamps/doc/en-us/VAMPS_Short_and_Long_Acting_Opioid_Daily_Dose_Limit.pdf

(Form continued on next page.)

Member's last name:

Member's first name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Preferred long-acting opioids (sch III-VI)	Butrans® Transdermal Patch	
Preferred long-acting opioids (sch II)	fentanyl 12, 25, 50, 75 & 100 mcg patches morphine sulfate ER tab	
Preferred short-acting opioids	codeine/APAP hydrocodone/APAP hydrocodone/ibuprofen hydromorphone morphine IR	oxycodone IR oxycodone/APAP tramadol HCl 50 mg tramadol HCl/APAP

Drug 1	Drug 2
Drug name/Form:	Drug name/Form:
Strength:	Strength:
Dosing frequency:	Dosing frequency:
Length of therapy:	Length of therapy:
Quantity per day:	Quantity per day:

Alternative therapy to schedule II opioids. Based on the Virginia Board of Medicine's Opioid Prescribing Regulations, Opioids are NOT recommended as first line treatment for acute or chronic pain. For additional information, please see VA Board of Medicine Regulations: <http://www.dhp.virginia.gov/medicine/>

Preferred pain relievers available without SA include NSAIDS (topical and oral), SNRIs, tricyclic antidepressants, gabapentin, baclofen, capsaicin topical cream 0.025%, lidocaine 5% patch, and pregabalin (Lyrica®). Consider alternative therapies to schedule II opioid drugs due to their high potential for abuse and misuse. A complete list of covered drugs can be found at: www.virginiamedicaidpharmacyservices.com/documents/VAMed-PDL-List-Criteria.

(Form continued on next page.)

Member's last name:

Member's first name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

TREATMENT INFORMATION

SA criteria align with the Virginia Board of Medicine's Regulations Governing Prescribing of Opioids and Buprenorphine: www.dhp.virginia.gov/medicine/

Length of authorization: 3 months based on the following diagnosis (please check all that apply):

- | | | |
|---------------------------------------|--|---|
| <input type="checkbox"/> HIV/AIDS | <input type="checkbox"/> Chronic back pain | <input type="checkbox"/> Arthritis |
| <input type="checkbox"/> Fibromyalgia | <input type="checkbox"/> Diabetic neuropathy | <input type="checkbox"/> Postherpetic neuralgia |
| <input type="checkbox"/> Other: _____ | | |

Length of authorization: 6 months based on the following diagnosis (please check all that apply):

- | | | |
|---|--|--|
| <input type="checkbox"/> Cancer pain | <input type="checkbox"/> Sickle cell disease | <input type="checkbox"/> Palliative care |
| <input type="checkbox"/> End-of-life care | <input type="checkbox"/> Hospice patient | |

- Does prescriber attest that the member has intractable pain associated with active cancer, palliative care (treatment of symptoms associated with life limiting illnesses), or hospice care? (IF YES, PLEASE SIGN AND SUBMIT, NO FURTHER INFORMATION REQUIRED unless a non-preferred/non-formulary drug is prescribed. See Question 5 if a non-preferred drug is prescribed.)
 Yes No
- Is member in remission from cancer and prescriber is safely weaning member off opioids with a tapering plan? (IF YES, PLEASE SIGN AND SUBMIT, NO FURTHER INFORMATION REQUIRED unless a non-preferred/ non-formulary drug is prescribed. See Question 5 if a non-preferred drug is prescribed.)
 Yes No
- Is member in a long-term care facility? **(IF YES, PLEASE SIGN AND SUBMIT, NO FURTHER INFORMATION REQUIRED** unless a non-preferred/non-formulary drug is prescribed. See Question 5 if a non-preferred drug is prescribed.)
 Yes No
- Please indicate if the member has tried and failed any of the following therapies covered without SA (*select all that apply*):

<input type="checkbox"/> Baclofen	<input type="checkbox"/> Capsaicin gel
<input type="checkbox"/> Duloxetine	<input type="checkbox"/> Gabapentin
<input type="checkbox"/> Lidocaine 5% patch	<input type="checkbox"/> NSAIDs (oral)
<input type="checkbox"/> Physical therapy	<input type="checkbox"/> Tricyclic antidepressant (e.g., nortriptyline)
<input type="checkbox"/> Cognitive behavioral therapy (CBT)	<input type="checkbox"/> Other: _____

(Form continued on next page.)

Member's last name:

Member's first name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

5. If requesting a non-preferred product (e.g., Avinza®, Kadian®, Embeda®), has the member tried and failed an adequate trial of 2 different preferred products?

Yes No

If **Yes**, please list drug names, length of trials, and reasons for discontinuation.

6. Provide the member's active daily MME from the PMP (virginia.pmpaware.net/login)

MME: _____

a. If member's active daily MME is greater than or equal to 90, does the prescriber attest that he/she will be managing the member's opioid therapy long term, has reviewed the Virginia BOM Regulations for Opioid Prescribing, has prescribed naloxone, and acknowledges the warnings associated with high-dose opioid therapy including fatal overdose, and that therapy is medically necessary for this member?

Yes No

7. Provide member's last fill date of opioid prescription from the PMP: _____

N/A

8. Provide member's last fill date of benzodiazepine prescription from the PMP: _____

a. If benzodiazepine was filled in past 30 days, does the prescriber attest that he/she has counseled the member on the FDA black box warning on the dangers of prescribing opioids and benzodiazepines including fatal overdose, has documented that the therapy is medically necessary, and has recorded a tapering plan to achieve the lowest possible effective doses of both opioids and benzodiazepines per the Board of Medicine Opioid Prescribing Regulations?

Yes No N/A

9. Has naloxone been prescribed for members with risk factors of overdose? Risk factors for overdose include substance use disorder, doses in excess of 50 MME/day, antihistamines, antipsychotics, benzodiazepines, gabapentin, pregabalin, tricyclic antidepressants, or the "Z" drugs (zopiclone, zolpidem, or zaleplon).

Yes No

10. If member is an 18–45-year-old female, has the prescriber discussed risk of neonatal abstinence syndrome and provided counseling on contraceptive options?

Yes No

(Form continued on next page.)

Member's last name:

Member's first name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

11. Does prescriber attest that a treatment plan with goals that addresses benefits and harm has been established with the member?

Yes No

If **No**, please explain:

12. For chronic pain, has the prescriber ordered and reviewed a urine drug screen (UDS) or serum medication level prior to initiating treatment with short- or long-acting opioids?

Yes No N/A

13. For SA renewals, has the prescriber ordered and reviewed a urine drug screen (UDS) or serum medication level at least every 3 months for the first year of treatment and at least every 6 months thereafter to ensure adherence?

Yes No N/A

Prescriber signature (Required)

Date

By signature, the Physician confirms the above information is accurate and verifiable by member records.

Please include ALL requested information; incomplete forms will delay the SA process.

Submission of documentation does NOT guarantee coverage by Molina Complete Care.

The completed form may be **faxed to 1-844-278-5731**, or you may call the number below.

CCC Plus: (800)-424-4524 (TTY/TDD: 711)

Medallion 4.0: (800)-424-4518 (TTY/TDD: 711)